Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer

摘要: Epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors are useful in treating different advanced human cancers; however, their clinical efficacy varies. This study detected K-ras mutations to predict the of EGFR-TK inhibitor cetuximab treatment on Chinese patients with metastatic colorectal cancer (mCRC). A total 87 were treated for 2-16 months, combination chemotherapy between August 2008 and July 2012, tissue samples used detect mutations. The data showed that mutation occurred 27/87 (31%). objective response rates disease control rate wild type mutant 42% (25/60) versus 11% (3/27) (p<0.05) 60% (36/60) 26% (7/27) (p<0.05), respectively. Patients wild-type had significantly higher median survival times progression-free survival, than mutated (21 months 17 p=0.017; 10 6 p=0.6). These findings suggest a high frequency occurs mCRC is required select eligibility therapy. Further prospective studies using large sample size needed confirm these preliminary findings.